Filing Flows › Autolus Therapeutics (AUTL) › Q1 2026 › vs Q1 2025
Autolus Therapeutics (AUTL) Q1 2026 vs Q1 2025 (year over year)
Autolus Therapeutics's revenue rose $17.2M (+192%) from $9.0M in Q1 2025 to $26.2M in Q1 2026.
Autolus Therapeutics, Q1 2026: revenue $26.2M (+192% year over year), operating margin -227.0%, net loss $71.6M, operating cash flow −$65.3M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $26.2M | $9.0M | $17.2M | +192% |
| Net loss | $71.6M | $70.2M | $1.4M | +2% |
| Costs & expenses | $97.8M | $79.1M | $18.7M | +24% |
| Operating costs | $85.7M | $74.2M | $11.5M | +16% |
| Interest & other, net | $11.2M | $2.7M | $8.5M | +316% |
| Income tax | $863K | $2.2M | −$1.4M | -61% |
| Cost of revenue | $24.6M | $18.0M | $6.6M | +37% |
| Research & development | $21.2M | $26.7M | −$5.5M | -21% |
| SG&A | $40.0M | $29.5M | $10.4M | +35% |
| Operating cash sources | $71.6M | $70.2M | $1.4M | +2% |
| Depreciation & amortization | $2.2M | $2.0M | $217K | +11% |
| Share-based compensation | $3.6M | $2.9M | $698K | +24% |
| Working capital & other | $507K | −$10.3M | $10.8M | — |
| Cash used in operations | $65.3M | $75.6M | −$10.2M | -14% |
| Net loss absorbed | $71.6M | $70.2M | $1.4M | +2% |
Questions
How much did Autolus Therapeutics's revenue grow year over year in Q1 2026?
Autolus Therapeutics's revenue rose $17.2M (+192%) from $9.0M in Q1 2025 to $26.2M in Q1 2026.